Bio-Rad Laboratories Inc (BIO) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Bio-Rad Laboratories Inc stock $202, price $382, that is 47.1% below the price, quality 69 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range $216.56 – $825.77 · fair‑value band $128.77 – $294.24 · the $381.57 price screens above the $201.81 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Bio-Rad Laboratories in your weekly email
Every Wednesday you see whether Bio-Rad Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics.
Show moreShow less
The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications.
This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories.
Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software.
The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Stock analysis
Bio-Rad Laboratories Inc (BIO) currently trades at $381.57, while our model-based Fair Value estimate is $201.81, 47% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $525.69 per share, and 7 of the 24 models we run sit above the $381.57 price.
Bear case: the Economic Profit group reads lowest at $145.43, and 17 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $128.77 (bear) to $294.24 (bull), the price of $381.57 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Bio-Rad Laboratories Inc reported revenue of $2.6B in FY2025 versus $2.9B in FY2021, a compound −3.0%/yr. Reported net income was $760M in FY2025, compounding −35.0%/yr from FY2021.
Key figures
Market cap $10.2B Large · P/E ratio 46.8 · P/S ratio 3.95 · EPS (TTM) $7.89 · Net margin 8.6% · Return on equity 3.1% · Return on assets (EBIT) 2.9% (5-year average) · Operating margin 11.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 44 out of 100 (low confidence).
What moves the price
The share trades about 2% below its 52-week high and 58% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −47%, BIO screens richer than that median.
Fair Value models
Bear$128.77Fair Value $201.81Bull$294.24
Price $381.57 · Downside -47.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($6.74 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, one officer or director sold shares worth $135,597 and none bought.
SaleEva Anette EngelhardtEVP, President, CDG550 shares at $246.54$135,597May 11, 2026
Plus 15 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
+0.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.3%
Start year 2020 (pandemic). Over 10 years: +2.5% a year
Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
−23.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−23.9%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−26.1% vs 24.8%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 11%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+15.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+1.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +12.5% a year for the price and −0.8% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (96 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: Bio-Rad benefits from double-digit growth in digital PCR via the Stilla acquisition yet faces uneven demand across academic and early-stage biotech markets together with modest returns.
Main risk: Software-first platforms and computational approaches such as AI-driven drug discovery or AI-interpreted cryo-EM could reduce demand for Bio-Rad's instruments and reagents by enabling fewer physical assays or alternative methods.
Bull case: Bio-Rad could integrate AI capabilities into its platforms to support AI-augmented research workflows and maintain relevance even as computational methods advance.
Bear case: If AI-driven alternatives and larger rivals erode demand for core instruments and reagents, Bio-Rad's life science segment could face sustained volume and pricing pressure with limited offsetting growth in diagnostics.
Bio-Rad is expanding its digital PCR offerings through the Stilla acquisition, which has driven double-digit growth in that segment amid applications in oncology and quality control. Yet demand stays uneven across academic and early-stage biotech markets while management restructures for mid-teens operating margins. Our models see the shares as overvalued, so will the shift to established products and cost cuts outpace the soft spots in research spending?
Compare Bio-Rad Laboratories Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks
Beats the industry median on 5/14 measures
Overall it trails its industry peers.
Valuation
Quality Score69 · Top 25%
Fair Value upside−47.1% · Below median
Profitability
Return on equity (12 months)3.1% · Below median
Return on assets7.2% · Top 25%
Net margin (12 months)8.6% · Above median
Operating margin (12 months)11.2% · Above median
Growth and dividend
Revenue growth (quarter YoY)−0.1% · Below median
Balance sheet
Debt / equity0.16× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)46.8× · Priciest 25%
P/B1.37× · Cheaper than median
P/S (12 months)3.95× · Pricier than median
Price / free cash flow (fiscal year)27.3× · Pricier than median
EV/EBITDA24.7× · Priciest 25%
PEG4.01× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 6
FUTURE (revenue growth)0· sector 35
PAST (return on equity)12· sector 17
HEALTH (low debt)92· sector 98
DIVIDEND (yield)0· sector 34
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Bio-Rad Laboratories Inc (BIO) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $201.81 versus a price of $381.57, about 47% lower (overvalued).
What is the fair value of BIO?
Our model-based fair value for Bio-Rad Laboratories Inc is $201.81 (as of Nov 6, 2026), built from audited fundamentals. The current price: $381.57.
What is the quality score of BIO?
Bio-Rad Laboratories Inc has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bio-Rad Laboratories Inc (BIO)?
Our model-based price target is the fair value of $201.81 (as of Nov 6, 2026) from 24 valuation models. Cautious scenario $128.77, optimistic scenario $294.24. It is a calculation from audited fundamentals, not an analyst target.
What is the Bio-Rad Laboratories Inc stock forecast for 2026?
Our models put fair value at $201.81, about 47% lower versus a price of $381.57 (overvalued). Cautious scenario $128.77, optimistic scenario $294.24. The calculation is refreshed regularly with new filings.
What is the revenue of Bio-Rad Laboratories Inc (BIO)?
Bio-Rad Laboratories Inc reported trailing-twelve-month revenue of about $2.6B (latest available figure, as of Nov 6, 2026).
What growth is priced into Bio-Rad Laboratories Inc (BIO)?
For today's price to be fair in a discounted-cash-flow model, Bio-Rad Laboratories Inc would have to grow free cash flow by +15.1 % per year for five years (discount rate 9.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.3 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of BIO use?
Our models discount Bio-Rad Laboratories Inc at 9.9 %: a base by market capitalisation (mid), damped by beta 1.06, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Bio-Rad Laboratories Inc that is +15.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.9 %) and the same formula as our fair value.
How much growth has Bio-Rad Laboratories Inc (BIO) delivered so far?
Over the past 5 years revenue at Bio-Rad Laboratories Inc grew +0.3 % a year. The price currently implies free-cash-flow growth of +15.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Bio-Rad Laboratories Inc (BIO) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Bio-Rad Laboratories Inc (+15.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Bio-Rad Laboratories Inc (BIO)?
The free-cash-flow yield on the price is 3.66 %: that much free cash flow Bio-Rad Laboratories Inc produces per unit of market value. When it exceeds the discount rate of our models (9.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Bio-Rad Laboratories Inc (BIO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bio-Rad Laboratories Inc it is $201.81 per share (as of Nov 6, 2026), against a price of $381.57. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Bio-Rad Laboratories Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, BIO trades above its calculated fair value: price $381.57, fair value $201.81, a gap of about −47% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BIO?
No. The price is what the market pays today ($381.57); the fair value is what the company's own numbers justify ($201.81). For Bio-Rad Laboratories Inc the two are $179.76 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bio-Rad Laboratories Inc worth?
The market values Bio-Rad Laboratories Inc at about $10.2B (market capitalisation, as of Nov 6, 2026). Per share that is $381.57; our models calculate a fair value of $201.81 per share.
What do the bullish and bearish scenarios say about BIO?
Our models span a range for Bio-Rad Laboratories Inc: cautious scenario $128.77, base $201.81, optimistic $294.24 per share (as of Nov 6, 2026, price $381.57). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BIO?
Bio-Rad Laboratories Inc trades at a price-to-earnings ratio of 46.8 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $201.81 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 38.5 (reported for FY2025: 13.6). Median P/E at fiscal year-end, 7 fiscal years (2016 to 2025), reported earnings, 4 of the years ex one-offs: 11.9. Other multiples: PEG 4.0, P/B 1.4, P/S 4.0, EV/EBITDA 24.7.
What is the PEG ratio of BIO?
The PEG ratio of Bio-Rad Laboratories Inc is 4.01 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Bio-Rad Laboratories Inc (BIO)?
Balance-sheet figures for Bio-Rad Laboratories Inc (as of Nov 6, 2026): return on equity 3.1%, debt of 0.16 per unit of equity. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is BIO from its 52-week high?
Bio-Rad Laboratories Inc trades at $381.57, about 2% below its 52-week high of $390.34 and 58% above the low of $241.71 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $201.81 is for.
Which stocks are comparable to Bio-Rad Laboratories Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bio-Rad Laboratories Inc stock attractive at the current price?
The data as of Nov 6, 2026: price $381.57, calculated fair value $201.81 (−47%), Quality Score 69/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BIO calculated?
We run Bio-Rad Laboratories Inc through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $201.81 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Bio-Rad Laboratories Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bio-Rad Laboratories Inc (BIO)?
The closing price on Nov 6, 2026 was $381.57. Our model-based fair value is $201.81, about 47% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bio-Rad Laboratories Inc right now?
The price sits above even our optimistic bull case ($294.24). The favourable scenario is already priced in. Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($128.77 to $294.24) leaves room in how you read the outcome.
Key figures of Bio-Rad Laboratories Inc
How large is the market capitalisation of Bio-Rad Laboratories Inc (BIO)?
The market capitalisation of Bio-Rad Laboratories Inc is $10.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bio-Rad Laboratories Inc (BIO)?
The price-to-sales ratio of Bio-Rad Laboratories Inc is 3.95 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bio-Rad Laboratories Inc (BIO)?
Earnings per share at Bio-Rad Laboratories Inc are $7.89 (price ÷ EPS = P/E 46.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Bio-Rad Laboratories Inc (BIO)?
The net margin of Bio-Rad Laboratories Inc is 8.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bio-Rad Laboratories Inc (BIO)?
The return on equity (ROE) of Bio-Rad Laboratories Inc is 3.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bio-Rad Laboratories Inc (BIO)?
On an EBIT basis the return on assets of Bio-Rad Laboratories Inc is 2.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bio-Rad Laboratories Inc (BIO)?
The operating margin of Bio-Rad Laboratories Inc is 11.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bio-Rad Laboratories Inc (BIO)?
Revenue at Bio-Rad Laboratories Inc is growing −0.1% versus a year earlier (3y avg −2.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bio-Rad Laboratories Inc (BIO)?
Earnings per share at Bio-Rad Laboratories Inc are growing +18.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Bio-Rad Laboratories Inc (BIO) carry?
The net debt of Bio-Rad Laboratories Inc is $999M (fiscal year 2025, ≈ 2.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Bio-Rad Laboratories Inc in the live analysis
One click puts Bio-Rad Laboratories Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026